Related Experiment Video
Updated: Mar 29, 2026
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Cerebral small vessel disease and Alzheimer's disease
Zhiyou Cai1, Chuanling Wang1, Wenbo He1
1Department of Neurology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei Province, People's Republic of China.
Insights
Cerebral small vessel disease (CSVD) contributes to Alzheimer's disease (AD). While statins may benefit both conditions, strong clinical evidence is currently lacking for specific drug applications.
Area of Science:
- Neurology
- Vascular Biology
- Neurodegenerative Diseases
Background:
- Cerebral small vessel disease (CSVD) encompasses pathological processes affecting small brain vessels, including lacunar infarcts, leukoaraiosis, and cerebral microbleeds.
- CSVD is a major cause of stroke (20% worldwide) and the primary driver of cognitive impairment and dementia, such as vascular dementia and Alzheimer's disease (AD).
- A significant link exists between CSVD and the development of AD.
Purpose of the Study:
- To explore the potential benefits of cerebrovascular disease treatments, particularly statins, for Alzheimer's disease.
- To investigate the current evidence supporting the use of specific drugs for managing both AD and CSVD concurrently.
Main Methods:
- Review of existing literature on CSVD, AD, and cerebrovascular disease treatments.
- Analysis of basic research and clinical studies investigating the interplay between CSVD and AD.
- Evaluation of evidence-based medicine regarding the efficacy of statins and other drugs in managing both conditions.
Main Results:
- Basic research suggests that treating cerebrovascular diseases may benefit AD.
- Current evidence-based medicine lacks strong support for the use of statins in treating AD via cerebrovascular pathways.
- Clinical application data for drugs targeting both AD and CSVD is limited.
Conclusions:
- CSVD is a critical factor in AD pathogenesis.
- While promising, the therapeutic potential of cerebrovascular disease treatments for AD requires further robust clinical validation.
- There is an unmet need for evidence-based clinical strategies and specific drugs to effectively manage both AD and CSVD simultaneously.
Abstract:
Cerebral small vessel disease (CSVD) is a group of pathological processes with multifarious etiology and pathogenesis that are involved into the small arteries, arterioles, venules, and capillaries of the brain. CSVD mainly contains lacunar infarct or lacunar stroke, leukoaraiosis, Binswanger's disease, and cerebral microbleeds. CSVD is an important cerebral microvascular pathogenesis as it is the cause of 20% of strokes worldwide and the most common cause of cognitive impairment and dementia, including vascular dementia and Alzheimer's disease (AD). It has been well identified that CSVD contributes to the occurrence of AD. It seems that the treatment and prevention for cerebrovascular diseases with statins have such a role in the same function for AD. So far, there is no strong evidence-based medicine to support the idea, although increasing basic studies supported the fact that the treatment and prevention for cerebrovascular diseases will benefit AD. Furthermore, there is still lack of evidence in clinical application involved in specific drugs to benefit both AD and CSVD.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22Alzheimer's Disease: Treatment
01:30Dementia
The progression of dementia is generally gradual....